AZN
AstraZeneca PLC
Stock
$156.90−0.80 (−0.51%)Close Oct 2, 2026
Income statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.7B | $54.1B | $45.8B | $44.4B | $37.4B | $26.6B | $24.4B | $22.1B | $22.5B | $23.0B | $24.7B |
| Cost of revenue | $10.6B | $10.2B | $8.3B | $12.4B | $12.4B | $5.3B | $4.9B | $4.9B | $4.3B | $4.1B | $4.6B |
| Gross profit | $48.1B | $43.9B | $37.5B | $32.0B | $25.0B | $21.3B | $19.5B | $17.2B | $18.1B | $18.9B | $20.1B |
| R&D | $14.2B | $13.6B | $10.9B | $9.8B | $9.7B | $6.0B | $6.1B | $5.9B | $5.8B | $5.9B | $6.0B |
| SG&A | $19.9B | $20.0B | $19.2B | $18.4B | $15.2B | $11.3B | $11.7B | $10.0B | $10.2B | $9.4B | $11.1B |
| Other operating expenses | $198M | $303M | — | — | — | — | — | — | — | — | — |
| Operating income | $13.7B | $10.0B | $8.2B | $3.8B | $1.1B | $5.2B | $2.9B | $3.4B | $3.7B | $4.9B | $4.1B |
| Non-operating income | −$1.3B | −$1.3B | −$1.3B | −$1.3B | −$1.3B | −$1.2B | −$1.4B | −$1.4B | −$1.5B | −$1.4B | −$1.0B |
| Pretax income | $12.4B | $8.7B | $6.9B | $2.5B | −$265M | $3.9B | $1.5B | $2.0B | $2.2B | $3.6B | $3.1B |
| Taxes | $2.2B | $1.7B | $944M | −$787M | −$377M | $720M | $213M | −$162M | −$774M | $53M | $244M |
| Net income | $10.2B | $7.0B | $6.0B | $3.3B | $112M | $3.2B | $1.3B | $2.2B | $3.0B | $3.5B | $2.8B |
| Diluted EPS | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 | $2.44 | $1.03 | $1.70 | $2.37 | $2.76 | $2.23 |
| Diluted shares | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B | 1.27B |
| Revenue growth | +8.6% | +18.0% | +3.3% | +18.5% | +40.6% | +9.2% | +10.4% | −1.7% | −2.3% | −6.9% | — |
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% | 81.2% |
| Operating margin | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% | 16.7% |
| Net margin | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% | 11.4% |